Comparing the current results to its competitors, Arrowhead Pharmaceuticals Inc reported Revenue increase in the 3 quarter 2026 by 171.02 % year on year. The sales growth was above Arrowhead Pharmaceuticals Inc 's competitors' average revenue growth of 4.99 %, achieved in the same quarter.
Due to outstanding performance in Overall company, revenue grew by 171.02 % Arrowhead Pharmaceuticals Inc improved its market share, to approximately 0.25 %.
October 21, 2025
In the ever-evolving landscape of pharmaceutical innovation, partnerships can significantly influence a company’s trajectory, particularly for those involved in cutting-edge therapies such as RNA interference (RNAi). Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR), known for its pioneering work in the field, recently solidified its strategic direction through two key collaborations: a global license and collaboration agreement with Novartis for its experimental therapy against alpha-synuclein and an ongoing agreement with Sarepta Therapeutics. This article delves into the implications of these agreements for Arrowhead Pharmaceuticals, dissecting how they might impact its portfolio, financial outlook, and po...
January 20, 2025
Arrowhead Pharmaceuticals, a leading biotechnology company based in Pasadena, California, has recently generated significant excitement in the pharmaceutical industry with two major announcements concerning its investigational therapy, plozasiran, and a strategic collaboration with Sarepta Therapeutics. These developments highlight Arrowhead s commitment to addressing rare genetic diseases and advancing innovative therapeutic approaches. Acceptance of New Drug Application for Plozasiran Arrowhead Pharmaceuticals announced the acceptance of its New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for plozasiran, a treatment aimed at managing familial chylomicronemia syndrome (FCS). This r...
October 15, 2024
Arrowhead Pharmaceuticals Inc. recently announced its inducement grants under NASDAQ Listing Rule 5635(c)(4), drawing attention to its financial status as the company navigates through a tumultuous year. During the twelve-month period ending in the third quarter of 2024, Arrowhead recorded a staggering cumulative net loss of $547 million. This figure reflects the complexities and challenges the biotechnology sector often faces, as companies invest heavily in research and development with the hope of future profitability.The reported loss has resulted in a negative return on investment (ROI) of -162.86%, positioning Arrowhead amongst the significant challenges characterized in the biopharmaceutical landscape....
August 21, 2024
Arrowhead Pharmaceuticals Advances RNAi Therapeutics: New Phase 3 Data, Obesity Candidates, and Strategic FinancingArrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) continues to drive innovation in the realm of RNA interference (RNAi) therapeutics, with significant developments anticipated at the upcoming European Society of Cardiology (ESC) Congress 2024. Scheduled in London from August 30 to September 2, the congress will serve as a platform for Arrowhead to present new Phase 3 clinical data from its PALISADE study of plozasiran (ARO-APOC3), a promising therapeutic for patients suffering from Familial Chylomicronemia Syndrome (FCS).The PALISADE study has garnered attention for its potential implications in t...
August 15, 2024
: Arrowhead Pharmaceuticals, a leading innovator in RNA interference (RNAi) technology, is poised to make significant strides in the battle against obesity and metabolic diseases. With its plans to advance two novel candidates, ARO-INHBE and ARO-ALK7, into clinical studies, the company aims to change the therapeutic landscape for these prevalent conditions. This article explores the underlying science, preclinical findings, and potential implications of these groundbreaking therapies.Obesity and related metabolic disorders remain critical global health challenges, with rising prevalence rates worldwide. Traditional methods of weight management often fall short, paving the way for innovative pharmaceutical so...
August 9, 2024
Arrowhead Pharmaceuticals Secures $500 Million Financing and Expands Workforce with New Inducement Grants Arrowhead Pharmaceuticals, Inc., a trailblazer in the field of RNA interference (RNAi) therapeutics, has made significant strides by securing a strategic financing agreement worth $500 million with Sixth Street. This move is aimed at further enhancing its robust pipeline and supporting innovation within the biotechnology sector. Alongside this strategic financing, the company has also announced the approval of inducement grants to new employees as part of its ongoing efforts to attract top talent. This article provides a comprehensive overview of Arrowhead s recent financial developments, operational en...
July 24, 2024
In a major announcement on August 8, 2024, Arrowhead Pharmaceuticals (NASDAQ: ARWR) revealed plans to host a highly anticipated webcast and conference call at 4:30 p.m. ET. This event aims to provide investors and stakeholders with a comprehensive overview of the company s financial performance during the fiscal third quarter, which concluded on June 30, 2024.Arrowhead Pharmaceuticals has gained a reputation as a pioneering force in the field of gene therapies, and this webcast offers a key opportunity for investors to gain insights into the latest advancements and projections within the industry. The live audio webcast can be accessed on the company s website, http://ir.arrowheadpharma.com/events.cfm, grant...
June 3, 2024
Arrowhead Pharmaceuticals Demonstrates Promising Results in Multiple Clinical Trials for Treatment of Genetic DiseasesArrowhead Pharmaceuticals, a leading biopharmaceutical company, has recently reported successful topline results from multiple clinical trials involving their investigational RNAi-based medicines. These trials focused on treating severe genetic diseases with significant unmet needs and have shown promising outcomes.One of the trials, known as the PALISADE study, evaluated the effectiveness of investigational plozasiran in patients with familial chylomicronemia syndrome (FCS). FCS is a rare genetic disorder characterized by high levels of triglycerides, which can lead to severe health complica...
April 26, 2024
Arrowhead Pharmaceuticals, a leading biopharmaceutical company, is set to make waves in the scientific community with its upcoming 2024 Summer Series of RandD webinars. The series will serve as a platform to highlight Arrowhead s groundbreaking clinical stage RNA interference (RNAi) based medicines, which leverage the company s revolutionary Targeted RNAi Molecule (TRiMTM) platform. RNAi technology has emerged as a game-changer in the field of medicine, offering immense potential for the treatment of a wide range of diseases. By selectively targeting and silencing disease-causing genes, Arrowhead s TRiMTM platform represents a significant step forward in the development of precise and personalized therapeuti...
March 25, 2024
Arrowhead Pharmaceuticals, a leading biopharmaceutical company, has recently launched an Expanded Access Program (EAP) to provide access to investigational plozasiran for patients suffering from familial chylomicronemia syndrome (FCS). This program aims to offer hope to patients who do not meet the eligibility criteria for clinical trials but still wish to access potential life-saving treatments. Additionally, Arrowhead Pharmaceuticals is set to present new final Phase 2 clinical data from the SHASTA-2 study of plozasiran in a late-breaking oral presentation.Familial chylomicronemia syndrome (FCS) is a rare genetic disorder characterized by the buildup of chylomicrons, which are large fat molecules, in the b...
Publicly Traded Peers of Arrowhead Pharmaceuticals Inc
Esperion Therapeutics Inc Share Performance
+169.49%
One Year
Esperion Therapeutics Inc
Profile
Esperion Therapeutics Inc's business model focuses on the development and commercialization of innovative therapies for addressing cardiovascular diseases.
Moonlake Immunotherapeutics's business model revolves around the development and commercialization of innovative immunotherapies for the treatment of diseases.
Mineralys Therapeutics Inc is a biotechnology company that follows the business model of developing and commercializing novel therapeutics for various diseases. They focus on discovering and advancing small molecule drugs based on innovative research approaches. Their business model is centered around conducting preclinical and clinical trials, obtaining regulatory approvals, and ultimately bringing their therapeutic products to market for improved patient outcomes.
MannKind Corporation is a biopharmaceutical company that focuses on the development and commercialization of inhaled therapeutic solutions for patients with diseases such as diabetes and pulmonary arterial hypertension. The company's business model revolves around conducting research and development to create innovative inhalation therapies and gaining regulatory approvals for these treatments. They then market and distribute their products, either directly or through partnerships, to healthcare providers and patients worldwide.
Medicinova Inc operates under a biopharmaceutical business model, primarily focused on the development and commercialization of innovative therapeutics. They strive to identify promising drug candidates with the potential to address unmet medical needs and advance them through clinical trials. By leveraging their research capabilities, strategic partnerships, and licensing opportunities, Medicinova Inc aims to bring these novel treatments to market and improve patient outcomes.
Sources:
Arrowhead Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Arrowhead Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
